Pharma Foods International Co.,Ltd. FY2026 FY Earnings Report

Quick View

Executive Summary

Despite lower revenue, operating income increased due to cost efficiencies, while the normalization of the tax burden significantly boosted net income; these were the key features of the current-period results. Revenue was ¥632.2B (-3.1% YoY), operating income was ¥26.3B (+11.2%), ordinary income was ¥24.4B (-4.4%), and net income was ¥19.9B (¥3.7B in the previous period, +440.2%). The primary driver of higher operating income was an improvement in the SG&A ratio resulting from restrained advertising expenses, while the sharp increase in net income was largely attributable to the reversal of the heavy tax burden recorded in the previous period.

Factors Affecting Earnings

【Revenue】Revenue declined 3.1% YoY to ¥632.2B. The core BtoC Business (87.6% of revenue mix) declined 2.4% to ¥553.7B, while the BtoB Business declined 8.7% to ¥74.7B. Only the Biomedical Business recorded a modest increase, rising 5.7% to ¥3.5B. Domestic sales account for more than 90% of total revenue, and growth remains dependent on customer acquisition trends in Japan’s D2C market.

【Profit and Loss】Operating income increased 11.2% YoY to ¥26.3B, and the operating margin improved by 60bp to 4.2% from 3.6% in the previous period. Although the gross margin declined slightly to 80.2% from 80.6% in the previous period due to a decrease in the cost of sales ratio, SG&A expenses, led by advertising expenses, declined 4.3% YoY and lifted the operating margin. Ordinary income declined 4.4% to ¥24.4B due to higher interest payments (¥0.9B→¥1.6B) and an increase in equity-method investment losses. Net income increased 440.2% to ¥19.9B, largely because the effective tax rate declined from 84.9% in the previous period to 14.5%; accordingly, much of the increase exceeding the improvement at the operating level was attributable to the normalization of the tax burden. Extraordinary losses of ¥1.2B included losses on the sale of shares in an affiliated company, but the amount was small and had a limited impact on net income. Overall, the results represent lower revenue but higher operating income.

Segment Analysis

The BtoC Business generated revenue of ¥553.7B (-2.4% YoY), operating income of ¥44.8B (+21.0%), and an 8.1% margin, achieving higher profit despite lower revenue through greater advertising efficiency. The BtoB Business recorded revenue of ¥74.7B (-8.7%), operating income of ¥11.1B (-10.9%), and a 14.9% margin, representing declines in both revenue and profit as demand from corporate customers remained weak. The Biomedical Business generated revenue of ¥3.5B (+5.7%) but posted an operating loss of ¥8.4B, expanding from a loss of ¥3.8B in the previous period; front-loaded research and development investment is diluting consolidated profitability. The improvement in consolidated operating income was driven almost entirely by greater advertising efficiency in the BtoC Business.

Key Financial Indicators

【Profitability】The operating margin improved to 4.2% from 3.6% in the previous period, a 60bp increase. However, the advertising expense ratio remained high at 53.6% against a gross margin of 80.2% (80.6% in the previous period), constraining the ultimate operating margin. The net margin improved significantly to 3.1% from 0.6% in the previous period, but the primary driver was the decline in the effective tax rate; this should not be viewed as being attributable solely to business improvements.【Cash Flow Quality】Operating cash flow (OCF) was negative ¥11.8B, creating a significant divergence from net income of ¥19.9B, and the OCF/net income ratio was negative 0.59x, indicating weak cash conversion. The main sources of pressure were a ¥12.9B increase in inventories and ¥25.3B in corporate income tax payments.【Investment Efficiency】ROE of 15.1% is at a favorable level, but the contribution from the increase in net margin and financial leverage (total assets/net assets) was significant. Evaluation should therefore take into account the weak support provided by operating cash flow. Capital expenditures amounted to ¥40.1B, while depreciation expense was only ¥7.0B, indicating a phase of front-loaded investment.【Financial Soundness】The equity ratio improved to 37.5% from 35.4% in the previous period. However, short-term borrowings accounted for a substantial portion of current liabilities of ¥182.7B, at ¥134.0B, and compared with cash and deposits of ¥77.9B, the Company has a high degree of dependence on refinancing for short-term liquidity. Long-term borrowings increased from ¥6.7B to ¥32.1B, indicating some progress toward extending the maturity of the funding structure.

Cash Flow Analysis

OCF was negative ¥11.8B (negative ¥10.9B in the previous period), marking the second consecutive period of negative OCF. The main sources of pressure were a ¥12.9B increase in inventories, a ¥5.1B decrease in trade payables, and ¥25.3B in corporate income tax payments. A ¥12.9B decrease in trade receivables partially offset these factors but was insufficient to cover them. Investing cash flow was negative ¥40.0B, primarily reflecting ¥40.1B in capital expenditures. As a result, free cash flow (OCF + investing cash flow) was negative ¥51.8B, representing a substantial funding shortfall. Financing cash flow was positive ¥38.1B, with a net increase of ¥20.0B in short-term borrowings and new long-term borrowings of ¥31.0B covering the shortfall in investment and working capital. The Company’s weak cash generation from operating activities and continued dependence on borrowings to fund capital expenditures and dividends require close monitoring when assessing the sustainability of its liquidity position.

Earnings Quality

The significant increase in net income to ¥19.9B (+440.2% YoY) was driven not only by the 11.2% increase in operating income but also substantially by the decline in the effective tax rate from 84.9% in the previous period to 14.5%. Caution is therefore required when interpreting the increase in net income as a direct indication of improved business conditions. In non-operating income and expenses, interest payments increased from ¥0.9B to ¥1.6B, while equity-method investment losses amounted to ¥2.0B. Consequently, ordinary income declined 4.4% to ¥24.4B, offsetting the increase in operating income. Extraordinary losses of ¥1.2B, including losses on the sale of shares in an affiliated company, were recorded, while extraordinary gains amounted to only ¥0.04B; thus, net income did not include a significant one-time boost. At the same time, OCF was negative ¥11.8B, diverging from accounting profit, and the high proportion of profit recognition accompanied by inventory accumulation indicates that earnings quality is relatively low compared with the improvement at the operating income level. Comprehensive income was ¥21.6B, slightly exceeding net income of ¥19.9B, with a positive ¥1.7B contribution from valuation differences on securities; however, the divergence between the two was not substantial.

Earnings Forecast and Guidance

Against the Company’s forecasts (revenue of ¥640.0B, operating income of ¥30.0B, ordinary income of ¥34.0B, EPS of ¥75.75, and dividend of ¥25.00), actual results for the current period reached 98.8% of the revenue forecast and 87.7% of the operating income forecast. Progress toward the ordinary income forecast was the lowest at 71.8%, and higher interest payments and equity-method investment losses may have been factors behind the shortfall at the ordinary income level. Net income was ¥19.9B and also appears to have fallen short of the Company’s forecast level (when viewed on an EPS basis), suggesting limited potential for an upward revision for the full year. While revenue was broadly in line with the plan, downside risk was relatively greater on the profit side.

Shareholder Returns

The annual dividend was ¥25.00 per share (¥12.50 interim and ¥12.50 year-end), doubling from ¥12.50 in the previous period. The payout ratio was 36.4%, below the 60% level generally regarded as an indicator of sustainability. However, current-period free cash flow was negative ¥51.8B, and dividend payments (¥7.2B in total) were not covered by free cash flow; in substance, shareholder returns depended on funding sources including borrowings. No share repurchases were identified during the current period. Accordingly, 36.4% should be assessed as the payout ratio, and reference to the total return ratio would not be appropriate. The Company’s dividend forecast also remains unchanged at ¥25.00, indicating that the current level is expected to be maintained for the time being; however, future improvement in OCF will determine the sustainability of the funding available for shareholder returns.

Risk Factors

1. Business concentration risk: The BtoC Business accounts for 87.6% of revenue, while the advertising expense ratio is also high at 53.6%. Increases in digital advertising unit prices or a decline in customer acquisition efficiency could directly affect the consolidated operating margin.

2. Liquidity and leverage risk: Short-term borrowings of ¥134.0B account for 80.7% of current liabilities, while cash and deposits of ¥77.9B cover only 0.58x this amount. OCF has been negative for two consecutive periods, and the Company continues to rely heavily on borrowings to fund investments and dividends.

3. Inventory and working capital risk: Inventories increased to ¥75.3B, up 19.4% YoY. The buildup of inventories is weighing on OCF, and errors in demand forecasts or product obsolescence could lead to impairment loss risk.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (food_beverage)

Profitability and Return

Both the operating margin and net margin are slightly below the industry median.

Growth and Capital Efficiency

The revenue growth rate is substantially below the industry median, placing the Company among the more notable revenue decliners within the industry.

※Source: Compiled by the Company

Key Points in the Financial Results

1. The operating margin improved by 60bp to 4.2%, but the high dependence on a cost structure with an advertising expense ratio of 53.6% means that the sustainability of profitability improvements will depend on maintaining advertising investment efficiency.

2. The significant increase in net income (+440.2%) was largely attributable to the normalization of the tax burden. Given that OCF remained negative at ¥11.8B, the divergence between earnings and cash flow is a structural point requiring observation.

3. The Company continues to depend on borrowings for funding due to increased inventories and expanded capital expenditures, including construction in progress. The operating status of these investments and trends in working capital will influence future financial performance.

Theoretical Stock Price (Reference Value)

Sensitivity: ¥547–¥579 at ±1% for the cost of equity, and ¥560–¥567 at ±0.1 for ω.

Note:

• Amortization of goodwill of ¥1.2/share is added back to earnings (to account for the non-cash expense and comparability with IFRS companies).

(Calculation model: Residual income model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-08 / Mechanically calculated value based solely on publicly available data; this is not a forecast of the market stock price or a recommendation of any specific investment action, and does not predict or guarantee the future stock price.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---